Sign In
Buy VTRS
$15.56
-0.130 (-0.83%)
At Close: Jun 03, 2026
ISCV Beat IJJ Over the Past Year. Here's Why That Gap Could Easily Reverse.
11:30am, Wednesday, 27'th May 2026
Compare expense ratios, diversification, and risk profiles as these two value-focused ETFs take distinct approaches to portfolio construction.
GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game.
11:17am, Wednesday, 27'th May 2026
A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure.
FDA Accepts Viatris' NDA for Fast-Acting Non-Opioid Pain Therapy
12:41pm, Tuesday, 19'th May 2026
VTRS' fast-acting meloxicam NDA enters FDA review as a non-opioid acute pain therapy, with a decision expected by Dec. 27, 2026.
Here's Why Viatris (VTRS) is a Strong Momentum Stock
10:50am, Monday, 18'th May 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
U.S. FDA Accepts Viatris New Drug Application for Fast-Acting Meloxicam for the Treatment of Moderate-to-Severe Acute Pain
08:00am, Monday, 18'th May 2026
FDA PDUFA Goal Date Set for Dec. 27, 2026 PITTSBURGH, May 18, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration
Why Viatris (VTRS) is a Top Value Stock for the Long-Term
10:40am, Wednesday, 13'th May 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
04:00pm, Tuesday, 12'th May 2026
Viatris Inc. (VTRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Why Viatris (VTRS) is a Top Growth Stock for the Long-Term
10:46am, Tuesday, 12'th May 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Viatris: From Cost Story To Pipeline-Driven Re-Rating (Rating Upgrade)
04:54am, Tuesday, 12'th May 2026
Viatris (VTRS) is upgraded to Strong Buy, underpinned by robust pipeline catalysts and a credible long-term growth framework. Viatris targets a five-year sales CAGR midpoint of 3.5%, exceeding consens
Viatris: The Cigar Butt Got Smoked, But I'm Holding The Rating
12:55pm, Monday, 11'th May 2026
Viatris Inc. delivered a clean Q1 2026 double beat driven almost entirely by Greater China, growing 18% operationally. The pipeline is finally shipping after years of underwhelming execution with Effe
Viatris to Present at the Bank of America Securities 2026 Healthcare Conference
04:30pm, Thursday, 07'th May 2026
PITTSBURGH, May 7, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the Bank of America Securities 2026 Healthcare Confer
Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater China
02:41pm, Thursday, 07'th May 2026
VTRS beats Q1 estimates as revenues climb 8% on strong Greater China and brands sales, while management reaffirms 2026 guidance.
Viatris Inc. (VTRS) Q1 2026 Earnings Call Transcript
02:21pm, Thursday, 07'th May 2026
Viatris Inc. (VTRS) Q1 2026 Earnings Call Transcript
Viatris beats quarterly estimates on China strength, branded drug sales
12:30pm, Thursday, 07'th May 2026
Viatris topped analysts' estimates for first-quarter revenue and profit on Thursday, buoyed by strength in its China business and strong demand for branded drugs.
Here's What Key Metrics Tell Us About Viatris (VTRS) Q1 Earnings
10:31am, Thursday, 07'th May 2026
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare t
